Michael Hagan, M.D., Ph.D., a professor of radiation oncology at Virginia Commonwealth University Massey Cancer Center and a Vietnam veteran, leads the VA Radiation Oncology program. Hagan had been serving as chief of radiation oncology at Hunter Holmes McGuire VA Medical Center in Richmond, Virginia for 12 years, continuing a Massey-VA partnership established in 1989 in which Massey provides a full spectrum of cancer care for Central Virginia’s veterans, including access to cutting-edge clinical trials. Hagan has been at the helm of the program since. “The Radiation Oncology Program was created to develop policies, guidelines and procedures to ensure that veterans are treated with radiation as safely and effectively as possible,” says Hagan.
Several years ago, Virginia Commonwealth University Massey Cancer Center became the first center in the United States to test an Israeli-invented device designed to increase the space between the prostate and the rectum in prostate cancer patients undergoing radiation therapy. Now, results from the international Phase I clinical trial show that the device has the potential to significantly reduce rectal injury, a side effect caused by unwanted radiation exposure that can leave men with compromised bowel function following treatment.
Translational Research Initiative for Pain and Neuropathy (TRIPN) hosts inaugural research symposium
On Tuesday, November 5, the VCU Translational Research Initiative for Pain and Neuropathy (TRIPN) hosted its inaugural symposium showcasing the latest developments in pain and neuropathy research.
VCU Massey Cancer Center partners with Children’s Hospital of Richmond at VCU to offer CAR T-cell therapy to children
This summer, VCU Massey Cancer Center in partnership with Children’s Hospital of Richmond at VCU (CHoR) became a certified treatment center for Novartis’ KYMRIAH, an FDA-approved CAR T-cell therapy for acute lymphoblastic leukemia in children and young adults. Massey was the first in Virginia to offer an FDA-approved CAR T-cell therapy last year with Gilead’s YESCARTA, and the addition of KYMRIAH is another milestone in providing expanded access to cutting-edge cellular immunotherapies.
Q&A with Dr. Kandace McGuire on new mammography guidelines from The American Society of Breast Surgeons
This week, The American Society of Breast Surgeons (ASBrS) issued new mammogram guidelines that recommend women of average risk of breast cancer should begin annual screening mammograms starting at age 40 and that women over 25 should undergo a formal risk assessment for breast cancer. Kandace McGuire, M.D., chief of breast surgery and director of the Breast Cancer Collaborative Care Clinic at VCU Massey Cancer Center, supports these new guidelines even though they differ from those suggested by the US Preventive Services Task Force (USPSTF) and the American Cancer Society (ACS).
In this Q&A, Dr. McGuire discusses the new guidelines and the reasons she supports them.